121 related articles for article (PubMed ID: 33527588)
21. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes.
Psutka SP; Heidenreich M; Boorjian SA; Bailey GC; Cheville JC; Stewart-Merrill SB; Lohse CM; Atwell TD; Costello BA; Leibovich BC; Thompson RH
BJU Int; 2017 Jan; 119(1):116-127. PubMed ID: 27489013
[TBL] [Abstract][Full Text] [Related]
22. Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients.
Du Y; Grüllich C; Hadaschik B; Hatiboglu G; Hohenfellner M; Pahernik S
Clin Genitourin Cancer; 2016 Aug; 14(4):e379-85. PubMed ID: 26971248
[TBL] [Abstract][Full Text] [Related]
23. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
[TBL] [Abstract][Full Text] [Related]
24. The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma.
Kang HW; Kim SM; Kim WT; Yun SJ; Lee SC; Kim WJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kim HH; Kwak C; Byun SS; Kim YJ;
J Cancer Res Clin Oncol; 2020 Jan; 146(1):187-196. PubMed ID: 31606760
[TBL] [Abstract][Full Text] [Related]
25. Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma.
Fujii Y; Ikeda M; Kurosawa K; Tabata M; Kamigaito T; Hosoda C; Okaneya T
Int J Clin Oncol; 2015 Aug; 20(4):802-7. PubMed ID: 25445164
[TBL] [Abstract][Full Text] [Related]
26. A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma.
Patel P; Nayak JG; Liu Z; Saarela O; Jewett M; Rendon R; Kapoor A; Black P; Tanguay S; Kawakami J; Moore R; Breau RH; Morash C; Pouliot F; Drachenberg DE
J Endourol; 2017 Jul; 31(7):645-650. PubMed ID: 28381117
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
28. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
[TBL] [Abstract][Full Text] [Related]
29. Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.
Sierra PS; Cordeiro MD; Albuquerque EV; Bastos DA; Bonadio RC; Sarkis AS; Cavalcante A; Pontes J; Coelho RF; Nahas WC
Clin Genitourin Cancer; 2020 Apr; 18(2):e134-e144. PubMed ID: 31980410
[TBL] [Abstract][Full Text] [Related]
30. Age at diagnosis is an independent predictor of small renal cell carcinoma recurrence-free survival.
Jeong IG; Yoo CH; Song K; Park J; Cho YM; Song C; Hong JH; Ahn H; Kim CS
J Urol; 2009 Aug; 182(2):445-50. PubMed ID: 19524959
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
32. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of high nuclear grade in patients with pathologic T1a renal cell carcinoma.
Suzuki K; Mizuno R; Mikami S; Tanaka N; Kanao K; Kikuchi E; Miyajima A; Nakagawa K; Oya M
Jpn J Clin Oncol; 2012 Sep; 42(9):831-5. PubMed ID: 22811408
[TBL] [Abstract][Full Text] [Related]
34. Oncological outcomes and prognostic factors after nephron-sparing surgery in renal cell carcinoma.
López-Costea MÁ; Bonet X; Pérez-Reggeti J; Etcheverry B; Vigués F
Int Urol Nephrol; 2016 May; 48(5):681-6. PubMed ID: 26861062
[TBL] [Abstract][Full Text] [Related]
35. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.
Ged Y; Chen YB; Knezevic A; Casuscelli J; Redzematovic A; DiNatale RG; Carlo MI; Lee CH; Feldman DR; Patil S; Hakimi AA; Russo P; Motzer RJ; Voss MH
Clin Genitourin Cancer; 2019 Jun; 17(3):e678-e688. PubMed ID: 31036466
[TBL] [Abstract][Full Text] [Related]
36. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
38. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Kawashima A; Tsujimura A; Takayama H; Arai Y; Nin M; Tanigawa G; Uemura M; Nakai Y; Nishimura K; Nonomura N;
Int J Urol; 2012 Dec; 19(12):1050-7. PubMed ID: 22860625
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
40. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma.
Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J
Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
